Artiva’s mission is to develop effective, safe and accessible cell therapies. Artiva’s lead program, AlloNK®, is an off-the-shelf NK cell therapy candidate designed to drive B-cell depletion in combination with monoclonal antibodies. AlloNK is currently in clinical trials for treatment of systemic lupus erythematosus and in a basket investigator-initiated trial in multiple autoimmune indications, and is also being developed in combination with acimtamig (AFM13, Affimed) in Hodgkin Lymphoma.